Full Text Journal Articles in
Journal Lancet Neurol

Advertisement

Find full text journal articles






Correction to Lancet Neurol 2021; 20: 49-59.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):e2]

Cited: 0 times

View full text PDF listing >>



Dementia and COVID-19: a health and research funding crisis.

Liesbeth Aerts, Elsa Lauwers, Bart De Strooper,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):90]

Cited: 0 times

View full text PDF listing >>



Advertisement

Correction to Lancet Neurol 2021; 20: 68-80.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):e2]

Cited: 0 times

View full text PDF listing >>



A new portrait by Géricault.

Javier S Burgos,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):90-91]

Cited: 0 times

View full text PDF listing >>



Michael Fehlings: translating evidence from bench to bedside.

Jules Morgan,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):92]

Cited: 0 times

View full text PDF listing >>



Maxime Baud.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):93]

Cited: 0 times

View full text PDF listing >>



Neurological burden and European investment: a disconnect.

The Lancet Neurology,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):81]

Cited: 0 times

View full text PDF listing >>



Neuromuscular junctions: mind meeting matter.

Richard R Ribchester, Arpan R Mehta,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):93]

Cited: 0 times

View full text PDF listing >>



Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care.

Giulia Fadda, Thais Armangue, Yael Hacohen, Tanuja Chitnis, Brenda Banwell,

The field of acquired CNS neuroimmune demyelination in children is transforming. Progress in assay development, refinement of diagnostic criteria, increased biological insights provided by advanced neuroimaging techniques, and high-level evidence for the therapeutic efficacy of biological agents are redefining diagnosis and care. Three distinct neuroimmune conditions-multiple sclerosis, myelin-oligodendrocyte glycoprotein antibody-associated ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(2):136-149]

Cited: 0 times

View full text PDF listing >>



Optimising prehospital stroke triage in a changing landscape.

Mayank Goyal, Martha Marko,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):166-168]

Cited: 0 times

View full text PDF listing >>



Comparison of eight prehospital stroke scales to detect intracranial large-vessel occlusion in suspected stroke (PRESTO): a prospective observational study.

Martijne H C Duvekot, Esmee Venema, Anouk D Rozeman, Walid Moudrous, Frédérique H Vermeij, Marileen Biekart, Hester F Lingsma, Lisette Maasland, Annemarie D Wijnhoud, Laus J M M Mulder, Kees C L Alblas, Roeland P J van Eijkelenburg, Bianca I Buijck, Jeannette Bakker, Aarnout S Plaisier, Jan-Hein Hensen, Geert J Lycklama À Nijeholt, Pieter Jan van Doormaal, Adriaan C G M van Es, Aad van der Lugt, Henk Kerkhoff, Diederik W J Dippel, Bob Roozenbeek, ,

<h4>Background</h4>Due to the time-sensitive effect of endovascular treatment, rapid prehospital identification of large-vessel occlusion in individuals with suspected stroke is essential to optimise outcome. Interhospital transfers are an important cause of delay of endovascular treatment. Prehospital stroke scales have been proposed to select patients with large-vessel occlusion for direct transport ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(3):213-221]

Cited: 0 times

View full text PDF listing >>



APOE and Alzheimer's disease: advances in genetics, pathophysiology, and therapeutic approaches.

Alberto Serrano-Pozo, Sudeshna Das, Bradley T Hyman,

The APOE ε4 allele remains the strongest genetic risk factor for sporadic Alzheimer's disease and the APOE ε2 allele the strongest genetic protective factor after multiple large scale genome-wide association studies and genome-wide association meta-analyses. However, no therapies directed at APOE are currently available. Although initial studies causally linked APOE ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):68-80]

Cited: 1 time

View full text PDF listing >>



A museum for Cajal's Legacy.

Javier DeFelipe, Juan A De Carlos, Arpan R Mehta,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):25]

Cited: 0 times

View full text PDF listing >>



Sleep research in 2020: COVID-19-related sleep disorders.

Markku Partinen,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):15-17]

Cited: 0 times

View full text PDF listing >>



Rapid drug access and scientific rigour: a delicate balance.

The Lancet Neurology,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):1]

Cited: 0 times

View full text PDF listing >>



Advances in traumatic brain injury research in 2020.

Danielle K Sandsmark, Ramon Diaz-Arrastia,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):5-7]

Cited: 0 times

View full text PDF listing >>



Bardia Nourbakhsh.

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):25]

Cited: 0 times

View full text PDF listing >>



Major advances in amyotrophic lateral sclerosis in 2020.

Orla Hardiman,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):14-15]

Cited: 0 times

View full text PDF listing >>



Headache research in 2020: disrupting and improving practice.

Peter J Goadsby,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):7-8]

Cited: 0 times

View full text PDF listing >>



Our health-care system is failing young people with epilepsy.

Dougal Hargreaves, Jane Hanna, Zachary M Grinspan, Colin Dunkley, Sonia Saxena, Helen Cross, ,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):26-27]

Cited: 0 times

View full text PDF listing >>



Neurological infections in 2020: COVID-19 takes centre stage.

Sarah Fredrich, Benjamin M Greenberg, Kimmo J Hatanpaa,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):17-18]

Cited: 0 times

View full text PDF listing >>



Dementia research in 2020: moving forward despite the COVID-19 pandemic.

Miia Kivipelto, Francesca Mangialasche,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):3-5]

Cited: 0 times

View full text PDF listing >>



Jacqueline Palace: a force for good in neuroimmune disorders.

Jules Morgan,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):24]

Cited: 0 times

View full text PDF listing >>



Multiple sclerosis in 2020: un bon cru.

Elisabeth Maillart, Catherine Lubetzki,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):12-13]

Cited: 0 times

View full text PDF listing >>



Epilepsy in 2020-a new dawn.

J Helen Cross,

Lancet Neurol (The Lancet. Neurology)
[2021, 20(1):8-10]

Cited: 0 times

View full text PDF listing >>



Advertisement

Disclaimer
0.7801 s